DGAP-News: Biofrontera AG / Key word(s): Miscellaneous
Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results
Conference calls for shareholders and interested investors will be held on Monday, April 29, 2019 at the following times:
In German, at 10:00 am CET (4:00 am ET)
In English, at 2:30 pm CET (8:30 am ET)
Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at .
16.04.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Hemmelrather Weg 201|
|Phone:||+49 (0)214 87632 0|
|Fax:||+49 (0)214 87632 90|
|ISIN:||DE0006046113, NASDAQ: BFRA|
|Listed:||Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq|
|EQS News ID:||800515|
|End of News||DGAP News Service|